Browse by author
Lookup NU author(s): Dr Adam McDiarmid
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2024 The Authors. Background: Hospitalized COVID-19 patients with troponin elevation have a higher prevalence of cardiac abnormalities than control individuals. However, the progression and impact of myocardial injury on COVID-19 survivors remain unclear. Objectives: This study sought to evaluate myocardial injury in COVID-19 survivors with troponin elevation with baseline and follow-up imaging and to assess medium-term outcomes. Methods: This was a prospective, longitudinal cohort study in 25 United Kingdom centers (June 2020 to March 2021). Hospitalized COVID-19 patients with myocardial injury underwent cardiac magnetic resonance (CMR) scans within 28 days and 6 months postdischarge. Outcomes were tracked for 12 months, with quality of life surveys (EuroQol-5 Dimension and 36-Item Short Form surveys) taken at discharge and 6 months. Results: Of 342 participants (median age: 61.3 years; 71.1% male) with baseline CMR, 338 had a 12-month follow-up, 235 had a 6-month CMR, and 215 has baseline and follow-up quality of life surveys. Of 338 participants, within 12 months, 1.2% died; 1.8% had new myocardial infarction, acute coronary syndrome, or coronary revascularization; 0.8% had new myopericarditis; and 3.3% had other cardiovascular events requiring hospitalization. At 6 months, there was a minor improvement in left ventricular ejection fraction (1.8% ± 1.0%; P < 0.001), stable right ventricular ejection fraction (0.4% ± 0.8%; P = 0.50), no change in myocardial scar pattern or volume (P = 0.26), and no imaging evidence of continued myocardial inflammation. All pericardial effusions (26 of 26) resolved, and most pneumonitis resolved (95 of 101). EuroQol-5 Dimension scores indicated an overall improvement in quality of life (P < 0.001). Conclusions: Myocardial injury in severe hospitalized COVID-19 survivors is nonprogressive. Medium-term outcomes show a low incidence of major adverse cardiovascular events and improved quality of life. (COVID-19 Effects on the Heart; ISRCTN58667920)
Author(s): Shiwani H, Artico J, Moon JC, Gorecka M, McCann GP, Roditi G, Morrow A, Mangion K, Lukaschuk E, Shanmuganathan M, Miller CA, Chiribiri A, Alzahir M, Ramirez S, Lin A, Swoboda PP, McDiarmid AK, Sykes R, Singh T, Bucciarelli-Ducci C, Dawson D, Fontana M, Manisty C, Treibel TA, Levelt E, Arnold R, Young R, McConnachie A, Neubauer S, Piechnik SK, Davies RH, Ferreira VM, Dweck MR, Berry C, Greenwood JP, Greenwood JP, McCann GP, Berry C, Dweck M, Miller CM, Chiribiri A, Prasad S, Ferreira VM, Bucciarelli-Ducci C, Dawson D, Davies R, Dweck M, Kelly B, Macfarlane PW, Goreka M, Somers K, Byrom-Goulthorp RJ, Anderson M, Britton L, Richards F, Jones LM, Moss A, Fisher J, Wormleighton J, Parke K, Wright R, Yeo J, Falconer J, Harries V, Henderson P, Newby D, Piechnik S, Popescu I, Zhang Q, Raman B, Channon K, Krasopoulos C, Nunes C, Da Silva Rodrigues L, Nixon H, Panopoulou A, Fletcher A, Manley P, Fallon K, Brown A, Kelly L, McGinley C, Briscoe M, Woodward R, Hopkins T, McLennan E, Tynan N, Dymock L, Swoboda P, Wright J, Exley D, Steeds R, Hutton K, MacDonald S, Treibel T, Shetye A, Miller CM, Orsborne C, Woodville-Jones W, Ferguson S, Bratis K, Fairbairn T, Sionas M, Widdows P, Chew PG, Marsden C, Collins T, George L, Kearney L, Flett A, Smith S, Zhenge A, Harvey J, Inacio L, Hanam-Penfold T, Gruner L, Razvi YSK, Crause J, Davies NM, Brown JT, Chaco L, Patel R, Kotecha T, Knight DS, Green T, Ripley D, Thompson M, Akerele U, Cifra E, Alskaf E, Crawley R, Villa A, Nightingale AK, Wright K, Bonnick ED, Hopkins E, George J, Joseph L, Cole G, Vimalesvaran K, Ali N, Carr CR, Ross AAR, King C, Prasad S, Farzad Z, Salmi SA, Kirby K, McDiarmid A, Stevenson HJ, Matsvimbo PS, Joji L, Fearby M, Brown B, Bunce N, Jennings R, Sookhoo V, Joshi S, Kanagala P, Fullalove S, Toohey C, Fenlon K, Bellenger N, He J, Statton S, Pamphilon N, Steele A, Ball C, McGahey A, Balma S, Wilkes L, Lewis K, Walter M, Ionescu A, Ninan T, Richards S, Williams M, Alfakih K, Pilgrim S, Joy G, Manisty CH, Hussain I
Publication type: Article
Publication status: Published
Journal: JACC: Cardiovascular Imaging
Year: 2024
Volume: 17
Issue: 11
Pages: 1320-1331
Print publication date: 01/11/2024
Online publication date: 28/08/2024
Acceptance date: 14/06/2024
Date deposited: 25/09/2024
ISSN (print): 1936-878X
ISSN (electronic): 1876-7591
Publisher: Elsevier Inc.
URL: https://doi.org/10.1016/j.jcmg.2024.06.008
DOI: 10.1016/j.jcmg.2024.06.008
Data Access Statement: Anonymized data can be shared with qualifying researchers after approval of a written proposal, by the Trial Management Committee, including senior statistical and clinical representation. A signed data access agreement is required.
PubMed id: 39207330
Altmetrics provided by Altmetric
